Apologies if this information has been presented before, it...

Apologies if this information has been presented before, it regards both HER-Vaxx and PD1-Vaxx.
As can be seen by the Recruitment Status they are both Active-Not Recruiting, this means that both trials are still open and patients are being assessed.The “Active, Not Recruiting” status in ClinicalTrials.gov is often misinterpreted. This status should only be used to indicate that “participants are still receiving an intervention or being examined, but new participants are not currently being recruited or enrolled”.
I hope this clears up any confusion about these trials status.

2 results sorted by trial registration date.

• Imugene

• A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas.

Registration number: NCT05311176

Broad health category: Cancer

Gastric Cancer

Cancer of Stomach

Gastric Adenocarcinoma

Stomach Cancer

Stomach Adenocarcinoma

astroesophageal Junction Adenocarcinoma

Trial focus: Treatment

Recruitment status:

Active, not recruiting

Recruitment sites:

NSW

SA

• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter).

Registration number: NCT04432207

Broad health category: Cancer

Non Small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB

Non-small Cell Lung Cancer Stage IV

Squamous Non-small-cell Lung Cancer

Large Cell Carcinoma Lung

Adenocarcinoma Lung

Trial focus: Treatment

Recruitment status:

Active, not recruiting

Recruitment sites:

NSW

VIC

DYOR opinion only